CD70 AND VENETOCLAX, A BCL-2 INHIBITOR, COMBINATION THERAPY FOR TREATING ACUTE MYELOID LEUKEMIA

摘要

The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapies include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof.